CRBP CLASS ACTION ALERT: Hagens Berman Alerts Corbus Pharmaceutical Holdings (NASDAQ: CRBP) Investors to May 13, 2019 Lead Plaintiff Deadline

03/15/2019

San Francisco - Hagens Berman Sobol Shapiro LLP alerts investors in Corbus Pharmaceutical Holdings, Inc. (NASDAQ: CRBP) to the May 13, 2019 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Massachusetts.  If you purchased or otherwise acquired Corbus Pharmaceutical securities between November 14, 2016 and February 28, 2019 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information about the case click

https://www.hbsslaw.com/cases/CRBP

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

CRBP@hbsslaw.com.

According to the complaint, during the class period Defendants misled investors about Corbus Pharmaceutical’s drug candidate Lenabasum by, among other things, changing the primary efficacy endpoint of the Lenabasum study after the Company was unblinded to the results and extending the efficacy readout to 16 weeks which was a full 4 weeks after patients were off the therapy.

On February 28, 2019, a SeekingAlpha contributor published an article highlighting the change and other potentially adverse matters.

This news drove the price of the Company’s shares down almost 16% to close at $6.94 that day.

“Among other matters, we’re focused on investors’ losses and whether Defendants may have misled investors concerning the Lenabasum study,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:  Persons with non-public information regarding Corbus Pharmaceutical Holdings should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email CRBP@hbsslaw.com.

# # #

About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 78 attorneys in 9 offices across the country.  The firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.

Contact:
Reed Kathrein, 510-725-3000


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Contact:

Please fill out the form below and we will get back to you as soon as we can.
 
*
*
*
*
*
*Required Field
Please list the date, quantity and share price of your purchases/sales during the Class Period so that we can calculate your losses. *
Upload your trade information. *
*
*
*
*
 

Case videos

Case Gallery

Case Timeline

03/14/19: Investigation